GlobalData on MSN5d
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravirGilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...
Potential to revolutionize HIV prevention. Ethel Weld, an Assistant Professor of Medicine at Johns Hopkins University School ...
ThePrint on MSN3d
Why Indian patients groups are opposing patent requests for blockbuster HIV drug lenacapavirGranting patents to US firm Gilead Sciences for lenacapavir could hinder global efforts to end AIDS & restrict access to ...
There are now multiple forms of injectable PrEP medications. Lenacapavir, which is Gilead's injectable drug, differs from ...
On September 19, 2024, the Indian Patent Office will hear objections filed by Sankalp Rehabilitation Trust against Gilead's ...
Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Gilead Sciences (NASDAQ: GILD), and ...
Twice-yearly lenacapavir was found to be superior to daily emtricitabine 200mg and tenofovir disoproxil fumarate 300mg.
Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, including with Merck’s islatravir, experts said. Early lenacapavir ...
In newly released data, lenacapavir, given via a twice-yearly injection, has shown remarkable effectiveness at eliminating ...
J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating on September 13. Chris Schott has ...
Leerink Partners analyst Daina Graybosch has maintained their neutral stance on GILD stock, giving a Hold rating on September 12. “Daina ...
A new study reveals that two yearly injections of the drug lenacapavir is more effective at preventing HIV than a daily pill ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback